Naproxen/esomeprazole
Combination of
NaproxenNSAID
EsomeprazoleProton pump inhibitor
Clinical data
Trade namesVimovo
AHFS/Drugs.comProfessional Drug Facts
Pregnancy
category
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 1234369-58-4
KEGG

Naproxen/esomeprazole, sold under the brand name Vimovo, is a pain reliever medication in the form of a tablet for oral consumption, containing naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and a delayed release formulation of esomeprazole, a stomach acid–reducing proton-pump inhibitor (PPI).[2][3] It is produced by AstraZeneca.[4] Vimovo is US Food and Drug Administration approved for use against osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.[2] It is intended to decrease the risk of gastric ulcers from treatment with NSAIDs.[2]

It is available as a generic medication.[5]

Adverse effects

See also: Naproxen § Adverse effects, and Esomeprazole § Adverse effects

Society and culture

Economics

Vimovo was acquired by the Ireland-based company, Horizon Pharma on November 19, 2013. AstraZeneca retained "ex-U.S. rights to Vimovo".[3]

In a June 2017 article in The Atlantic, journalist Marshall Allen wrote that, the cost of Aleve and Nexium, the two common medications" that became the specialty drug Vimovo, was $40 a month. Horizon Pharma bills insurance companies $3,252 a month for Vimovo.[6] According to The Atlantic, "since 2014, Horizon Pharma's net sales have been more than $455 million".[6]

References

  1. ^ "Esomeprazole / naproxen (Vimovo) Use During Pregnancy". Drugs.com. 11 September 2019. Retrieved 17 August 2020.
  2. ^ a b c d "Vimovo- naproxen and esomeprazole magnesium tablet, delayed release". DailyMed. Retrieved 5 May 2021.
  3. ^ a b "Horizon Pharma Announces Agreement to Acquire U.S. Rights to Vimovo and Provides 2014 Guidance". Horizon Pharma, Inc. (Press release). Deerfield, Illinois. November 19, 2013.
  4. ^ "Vimovo-Astrazeneca". felleskatalogen.no.
  5. ^ https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022511
  6. ^ a b Allen, Marshall (June 20, 2017). "How Two Common Medications Became One $455 Million Specialty Pill". The Atlantic. Retrieved June 20, 2017. After I was prescribed a brand-name drug I didn’t need and given a coupon to cover the out-of-pocket costs, I discovered yet another reason why Americans pay too much for health care.